Advertisement

Column 16. What Is the Actual Status of Radiotherapy (External Beam Radiotherapy and 131I MIBG Therapy)?

  • Seigo Kinuya
  • Naoyuki Shigematsu
  • Yasushi Noguchi
  • Tatsuya Higashi
Chapter

Abstract

Evidence is lacking for external beam radiotherapy for medullary carcinoma, and its significance remains unknown. A therapy using 131I MIGB, which is a norepinephrine analogue, can be performed domestically when an individual patient imports 131I MIGB for his/her own use. It is impossible to perform radioimmunotherapy using Y-90-DOTATOC, a somatostatin analogue, and an anti-CEA antibody in Japan, although some reports have been published in Western countries.

Keywords

Neuroendocrine Tumor External Beam Radiotherapy Medullary Thyroid Carcinoma Medullary Carcinoma Uptake MIBG 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Schwartz DL, Rana V, Shaw S et al (2008) Postoperative radiotherapy for advanced medullary thyroid cancer—local disease control in the modern era. Head Neck 30:883–888 (RS)PubMedCrossRefGoogle Scholar
  2. 2.
    Nakajo M, Yoshinaga K, Oriuchi N et al (2008) (Text in Japanese) Kakuigaku 45:1–40(Suppl) (Others)Google Scholar
  3. 3.
    Mukherjee JJ, Kaltsas GA, Islam N et al (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-meta-iodobenzylguanidine[131I-mIBG]. Clin Endocrinol (Oxf) 55:47–60 (RS)CrossRefGoogle Scholar
  4. 4.
    Shapiro B (1991) Summary, conclusions, and future directions of[131I]metaiodobenzylguanidine therapy in the treatment of neural crest tumors. J Nucl Biol Med 35:357–363 (NR)PubMedGoogle Scholar
  5. 5.
    Troncone L, Rufini V (1997) 131I-MIBG therapy of neural crest tumours (review). Anticancer Res 17:1823–1831 (NR)PubMedGoogle Scholar
  6. 6.
    Tsukamoto E, Yoshinaga K, Tamaki N (2001) (Text in Japanese) Eizo Joho Med 33:1076–1080 (CaseR)Google Scholar
  7. 7.
    Castellani MR, Chiti A, Seregni E et al (2000) Role of 131I-metaiodobenzylguanidine(MIBG)in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med 44:77–87 (RS)PubMedGoogle Scholar
  8. 8.
    Iten F, Muller B, Schindler C et al (2007) Response to[90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 13:6696–6702 (PS)PubMedCrossRefGoogle Scholar
  9. 9.
    Bodei L, Handkiewicz-Junak D, Grana C et al (2004) Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 19:65–71 (RS)PubMedCrossRefGoogle Scholar
  10. 10.
    Chatal JF, Campion L, Kraeber-Bodéré F et al (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24:1705–1711 (RS)PubMedCrossRefGoogle Scholar
  11. 11.
    Sharkey RM, Hajjar G, Yeldell D et al (2005) A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46:620–633 (PS)PubMedGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Seigo Kinuya
    • 1
  • Naoyuki Shigematsu
    • 2
  • Yasushi Noguchi
    • 3
  • Tatsuya Higashi
    • 4
  1. 1.Department of Nuclear Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health ScienceKanazawa UniversityKanazawaJapan
  2. 2.Department of RadiologyKeio University School of MedicineTokyoJapan
  3. 3.Department of RadiologyNoguchi Thyroid Clinic and Hospital FoundationBeppuJapan
  4. 4.Shiga Medical Center Research InstituteOtsu-shiJapan

Personalised recommendations